Andogsky Syndrome: Experience with Anti-IL-4,13 Therapy

  • Authors: Mukhina O.A.1,2, Bobrikova E.N.3, Savinkova C.Y.3, Mayorova I.V.3, Lebedkina M.S.3, Murashkin N.N.4,5,6, Lvov A.N.7,8, Karaulov A.V.9, Lysenko M.A.3,10, Fomina D.S.3,9,11
  • Affiliations:
    1. State Budgetary Healthcare Institution of Moscow City "Moscow Clinical Research Center
    2. Research Institute of Healthcare Organization and Medical Management of Moscow Department of Healthcare
    3. State Budgetary Healthcare Institution of Moscow City "Moscow Clinical Research Center Hospital No. 52 of the Moscow City Health Department"
    4. National Medical Research Center for Children’s Health
    5. The First Sechenov Moscow State Medical University (Sechenov University)
    6. Central State Medical Academy
    7. Central State Medical Academy of Department of Presidential Affairs
    8. Lomonosov Moscow State University
    9. Federal State Autonomous Educational Institution of Higher Education I.M.Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenovskiy University)
    10. The Russian National Research Medical University named after N.I. Pirogov
    11. Astana Medical University
  • Section: Case reports
  • Submitted: 17.08.2025
  • Accepted: 19.09.2025
  • Published: 19.09.2025
  • URL: https://rusalljournal.ru/raj/article/view/17048
  • DOI: https://doi.org/10.36691/RJA17048
  • ID: 17048


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Andogsky syndrome with signs of T2 inflammation and ectodermal structure involvement is a complex disease characterized by a combination of atopic dermatitis and progressive juvenile cataracts. The high risks of disability in young patients, due to the danger of developing persistent visual impairments, require special attention to this patient group. Measures aimed at controlling inflammation, preventing ophthalmological complications, and timely surgical intervention, if necessary, require constant dynamic monitoring by an allergist-immunologist and an ophthalmologist. The therapeutic strategy for severe Andogsky syndrome involves a comprehensive interdisciplinary approach with the rational use of modern systemic therapy. Dupilumab, a monoclonal antibody targeting the alpha subunit of the interleukin (IL)-4 and IL-13 receptor, has dramatically changed the treatment approach for atopic conditions such as atopic dermatitis (AD), bronchial asthma, and chronic rhinosinusitis. However, its expanding use has drawn increased attention to several undesirable ocular adverse events — conjunctivitis, blepharitis, keratitis, corneal ulcers, and cicatricial conjunctivitis — which remain underrecognized and often underestimated in clinical practice. These manifestations frequently occur in patients with atopic dermatitis and vary in severity, creating diagnostic and therapeutic challenges. The therapeutic potential of Dupilumab in treating Andogsky syndrome is of particular interest, given the complex nature of the disease and the involvement of various body systems. Suppression of T2 inflammation through inhibition of IL-4 and IL-13 leads to: reduction in the severity of skin manifestations, decrease in inflammatory process intensity, improvement in ophthalmological indicators. Further study of Dupilumab’s effectiveness in Andogsky syndrome will allow determining the optimal duration of therapy, assessing the impact on disease progression, developing personalized treatment approaches.

Full Text

Restricted Access

About the authors

Olga A. Mukhina

State Budgetary Healthcare Institution of Moscow City "Moscow Clinical Research Center;
Research Institute of Healthcare Organization and Medical Management of Moscow Department of Healthcare

Author for correspondence.
Email: mukhina.o.a@gmail.com
ORCID iD: 0000-0002-3794-4991
SPIN-code: 7721-1941

Врач аллерголог-иммунолог

Россия, 123182, Russia, Moscow, 3 Pekhotnaya Street; 115184, Russia, Moscow, Bolshaya Tatarskaya Street, building 30.

Elena N. Bobrikova

State Budgetary Healthcare Institution of Moscow City "Moscow Clinical Research Center
Hospital No. 52 of the Moscow City Health Department"

Email: elena.bobrikova.69@mail.ru
ORCID iD: 0000-0002-6534-5902
SPIN-code: 5806-7260

Заведующая КДО аллергологии и иммунологии, врач аллерголог-иммунолог

Россия, 3 Pekhotnaya Street, Moscow, 123182, Russia

Christina Yu Savinkova

State Budgetary Healthcare Institution of Moscow City "Moscow Clinical Research Center
Hospital No. 52 of the Moscow City Health Department"

Email: popova.derm@gmail.com
ORCID iD: 0000-0002-7855-6207
SPIN-code: 5794-9317

Врач дерматовенеролог

3 Pekhotnaya Street, Moscow, 123182, Russia

Irina V. Mayorova

State Budgetary Healthcare Institution of Moscow City "Moscow Clinical Research Center
Hospital No. 52 of the Moscow City Health Department"

Email: allersaganrin@gmail.com
ORCID iD: 0009-0003-0984-7419
SPIN-code: 2021-4401

Врач аллерголог-иммунолог

Россия, 3 Pekhotnaya Street, Moscow, 123182, Russia

Marina S. Lebedkina

State Budgetary Healthcare Institution of Moscow City "Moscow Clinical Research Center
Hospital No. 52 of the Moscow City Health Department"

Email: marina.ivanova0808@yandex.ru
ORCID iD: 0000-0002-9545-4720
SPIN-code: 1857-8154

Врач аллерголог-иммунолог

Россия, 3 Pekhotnaya Street, Moscow, 123182, Russia

Nikolay N. Murashkin

National Medical Research Center for Children’s Health; The First Sechenov Moscow State Medical University (Sechenov University); Central State Medical Academy

Email: m_nn2001@mail.ru
ORCID iD: 0000-0003-2252-8570
SPIN-code: 5906-9724

MD, Dr. Sci. (Medicine), Professor

Россия, Moscow; Moscow; Moscow

Andrey N. Lvov

Central State Medical Academy of Department of Presidential Affairs; Lomonosov Moscow State University

Email: alvov@mail.ru
ORCID iD: 0000-0002-3875-4030
SPIN-code: 1053-3290

MD, Dr. Sci. (Med.), Professor

Россия, Moscow; Moscow

Alexander V. Karaulov

Federal State Autonomous Educational Institution of Higher Education I.M.Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenovskiy University)

Email: drkaraulov@mail.ru
ORCID iD: 0000-0002-1930-5424
SPIN-code: 4122-5565

MD, Dr. Sci. (Med.), Professor, academician of the Russian Academy of Sciences

Россия, Moscow

Maryana A. Lysenko

State Budgetary Healthcare Institution of Moscow City "Moscow Clinical Research Center
Hospital No. 52 of the Moscow City Health Department";
The Russian National Research Medical University named after N.I. Pirogov

Email: gkb52@zdrav.mos.ru
ORCID iD: 0000-0001-6010-7975
SPIN-code: 3887-6250

MD, Dr. Sci. (Medicine), Professor

Россия, Moscow; Moscow

Darya S. Fomina

State Budgetary Healthcare Institution of Moscow City "Moscow Clinical Research Center
Hospital No. 52 of the Moscow City Health Department"; Federal State Autonomous Educational Institution of Higher Education I.M.Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenovskiy University); Astana Medical University

Email: daria_fomina@mail.ru
ORCID iD: 0000-0002-5083-6637
SPIN-code: 3023-4538
Scopus Author ID: 57201133822

PhD, Associate Professor

Россия, Moscow; Moscow; Astana, Kazakhstan

References

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright © ABV-press,



This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies